Exhibit 32
WAVE LIFE SCIENCES LTD.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Amendment No. 2 to Annual Report of Wave Life Sciences Ltd. (the “Company”) on Form10-K/A for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
May 9, 2018
/s/ Paul B. Bolno, M.D. |
| Paul B. Bolno, M.D. |
President and Chief Executive Officer (principal executive officer) |
May 9, 2018
/s/ Keith C. Regnante |
| Keith C. Regnante |
Chief Financial Officer (principal financial officer and principal accounting officer) |
This certification accompanies the Form10-K/A to which it relates is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form10-K/A), irrespective of any general incorporation language contained in such filing.
